Nac Al (Acetylcysteine)

Acetylcysteine reduces mucus viscosity by breaking disulfide bonds in the glycoprotein matrix of airway secretions. This chemical action creates thinner mucus that can be more readily moved by ciliary action. Additionally, the compound supplies cysteine for glutathione synthesis, supporting antioxidant defenses in the respiratory epithelium.

The appropriate dose of Nac Al is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other individual factors. Dosage regimens are not standardized in this description and should follow the prescriber’s instructions and local labeling.

Safety data for acetylcysteine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers must evaluate each case individually and discuss potential risks with the patient.

To request Nac Al, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Acetylcysteine (Nac Al) differs from other mucolytics such as carbocysteine or ambroxol in its mechanism; it directly cleaves disulfide bonds and also replenishes glutathione. While carbocysteine primarily modifies mucus production, ambroxol stimulates ciliary activity. Choice of agent depends on clinical response, tolerance, and physician preference.

Nac Al should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Nac Al is administered orally. The tablet or capsule (as supplied) should be taken with a full glass of water, preferably after a meal to reduce gastrointestinal discomfort. Patients should follow the prescriber’s instructions regarding timing and whether the dose should be taken with or without food.

Serious adverse reactions, although rare, include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, bronchospasm, hepatic dysfunction and neutropenia. Immediate medical attention is required if any signs of severe allergy, breathing difficulty, jaundice, or unexplained blood abnormalities occur.

Nac Al should be avoided in individuals with known hypersensitivity to acetylcysteine or any of its excipients. Patients with severe uncontrolled asthma, a history of bronchospasm after mucolytic therapy, or significant hepatic impairment should not use the product without close medical supervision.